Design and synthesis of orally active pyrrolidin-2-one-based factor Xa inhibitors
Nigel S. Watson(GlaxoSmithKline (United Kingdom)), Robert J. Young(Age UK), Claudine Haslam(GlaxoSmithKline (United Kingdom)), Rebecca Fenwick(GlaxoSmithKline (United Kingdom)), Laiq Chaudry(GlaxoSmithKline (United Kingdom)), Vipulkumar K. Patel(GlaxoSmithKline (United Kingdom)), Andrew R. Leach(LifeArc), Stefan Senger(GlaxoSmithKline (United Kingdom)), Gita P. Shah(GlaxoSmithKline (United Kingdom)), Andrew M. Mason(GlaxoSmithKline (United Kingdom)), Caroline Whitworth, M.A. Convery(GlaxoSmithKline (United Kingdom)), Henry A. Kelly(GlaxoSmithKline (United Kingdom)), Gary R. Manchee(GlaxoSmithKline (United Kingdom)), Helen E. Weston, Cynthia L. Kurtis(GlaxoSmithKline (United States)), David Brown(Institut polytechnique de Grenoble), Matthew Campbell(GlaxoSmithKline (United Kingdom)), Champa Patel(GlaxoSmithKline (United Kingdom)), Chuen Chan(GlaxoSmithKline (United Kingdom)), J. Hamblin(GlaxoSmithKline (United Kingdom)), N. Paul King(GlaxoSmithKline (United Kingdom)), Charlotte Mitchell(GlaxoSmithKline (United Kingdom))
Cited by 30
Related Papers
Development and validation of a genetic algorithm for flexible docking 1 1Edited by F. E. Cohen
|Journal of Molecular Biology|1997|6.7k
ChEMBL: towards direct deposition of bioassay data
|Nucleic Acids Research|2018|2.5k
The ChEMBL database in 2017
|Nucleic Acids Research|2016|2.4k
Molecular Modelling: Principles and Applications
|Unknown|1996|1.9k
An analysis of the attrition of drug candidates from four major pharmaceutical companies
|Nature Reviews Drug Discovery|2015|1.4k